This Is MS Multiple Sclerosis Community: Knowledge & Support

Research details of a drug that may help people with secondary progressive multiple sclerosis (MS), developed by New Zealand biopharmaceutical company Innate Immunotherapeutics, is being highlighted at the world’s biggest annual gathering of MS specialists and pharmaceutical companies, ECTRIMS, in Lyon, France today.

Innate’s study co-principal investigator, Dr Alison Luckey, talk about the result of 1B/2A trials of its drug MIS416 in the late breaking news section of ECTRIMS. More than 6,000 people attend the conference.

Simon Wilkinson, chief executive of Innate Immunotherapeutics, says results of the Phase 1/2 clinical trial have shown MIS416 to be well tolerated and identified a clinical dose for further evaluation.

"For most international clinicians and researchers into MS this will be the first time they will heard about our drug, that it has been in early stage trials and most importantly that early results are encouraging," he says. "We are grateful for the support of the United States National MS Society at ECTRIMS, especially for the credibility and validation of our programme the society’s support provides."... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/3505

_________________
The Multiple Sclerosis Resource Centre

Squiffy's House of Fun - Laughter for Multiple Sclerosis

Another immune system altering drug used on cancer and showing promising results on the MS Mouse! Sure hope it does the same for MS patients.

I understand that no large scale trials on effectiveness on MS (ie humans, not EAE), but there appears to be a total lack of any information regarding HOW effective (ie numbers & %) the treatment was in trials they have done thus far. I also appeared to have missed any indication of how it actually works? immune suppression?

They appear to be placing a number of publicity shots for maybe revenue raising, not so much because it is "so" effective.

"Peliminary data indicate that MIS416 was safe and well tolerated, and the MS-related clinical status assessment tools used during the study also indicate that the trial agent may have had some positive effect for many of the treated patients,"

Hmmm...well tolerated and "may" indicate some positive effect said neurologist Professor Tim Anderson, M.D., co-principal investigator for the study. This was with 10 patients.

Now if this was a drug or therapy being talked about by anyone outside of the mainstream MS world of medicine, the criticism that would be thrown against it with such a small number of patients would be immense. It would be dismissed and ridiculed. But the NMSS is associated with the research so it gets coverage and publicity. I guess it's not what you know but whom you know.

Harry

This was on the news here the other night.

http://tvnz.co.nz/national-news/christc ... nt-5297796

It seems there are several people taking the drug after the trial because they don't want to go back to life before the drug. It is interesting to me because very few treatments are for ppms or spms but this one is. The next phase of the trial is in Australia.

Hmmm....I think we've read in the past that there is debate whether the immune system is gone rogue on itself or is simply reacting to what is going on in the MS patient's system. In other words, there is another process that is causing the immune system to react the way it does. Always more questions than answers when it comes to MS!

Harry

To give thins perspective, I always compare statements against what was coming out about Aimspro, which also never really eventuated as hoped and believed by many.

But that is interesting to me.